

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the annual general meeting (the “AGM”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) will be held at 9:00 a.m. on June 20, 2025 at Meeting Room 1, R&D Building, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, Sichuan Province, the People's Republic of China for the following purposes:

ORDINARY RESOLUTIONS

1. To consider and approve the financial budget report of the Company for the year 2025.
2. To consider and approve the report of the Board of Directors for the year 2024.
3. To consider and approve the report of the Supervisory Committee for the year 2024.
4. To consider and approve the annual report of the Company for the year 2024.
5. To consider and approve the re-appointment of KPMG as the auditors of the Company for the year 2025, for a term commencing from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company, and to authorize the Board of Directors to determine the specific matters, including but not limited to their remuneration of not more than RMB2,800,000 for the year 2025 before tax, in relation to such appointment.
6. To consider and approve (i) the remuneration plan for the Directors of the fourth session of the Board and (ii) the remuneration plan for the Directors of the third session of the Board and for the Supervisors of the third session of the Supervisory Committee from the period of January 1, 2025 until the expiry of their respective terms of office.
7. To consider and approve the annual profit distribution plan of the Company for the year 2024.
8. To consider and approve the acquisition of wealth management products with idle self-owned funds for the year 2025, with the details as set out in the circular of the Company dated May 21, 2025 (the “**Circular**”).

9. To consider and approve the election of:
- (a) Mr. LIU Gexin as a non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (b) Mr. LIU Sichuan as a non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (c) Mr. LAI Degui as a non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (d) Mr. FENG Hao as a non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (e) Ms. LIAO Yihong as a non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (f) Mr. ZENG Xuebo as a non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (g) Dr. ZHENG Qiang as an independent non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (h) Dr. TU Wenwei as an independent non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected;
 - (i) Dr. JIN Jinping as an independent non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected; and
 - (j) Dr. LI Yuedong as an independent non-executive Director of the fourth session of the Board with effect from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company at which a new session of the Board will be elected.
10. To consider and approve the proposed amendments to the rules of procedure of the independent non-executive Directors as set out in Annex IV to the Circular.

SPECIAL RESOLUTIONS

11. To consider and approve the grant of a general mandate to the Board to issue Shares and sell Treasury Shares, with the details of the general mandate as set out in the Circular.
12. To consider and approve the grant of a general mandate to the Board to repurchase H Shares, with the details of the general mandate as set out in the Circular.
13. To consider and approve the proposed amendments to the articles of association of the Company and its appendices as set out in Annex III to the Circular.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, May 21, 2025

Notes:

1. All resolutions at the AGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the websites of the Company at <https://kelun-biotech.com> and Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk after the AGM.
2. Any Shareholder entitled to attend and vote at the AGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a Shareholder of the Company.
3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares), at least 24 hours before the AGM (i.e. before 9:00 a.m. on June 19, 2025) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a Shareholder from attending and voting at the AGM or any adjourned meeting thereof should he/she so wish.
4. For the purpose of determining the list of Shareholders who are entitled to attend the AGM, the register of members of the Company will be closed from June 17, 2025 to June 20, 2025, both days inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the AGM, unregistered Shareholders shall ensure all transfer documents accompanied by the relevant share certificates are lodged with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on June 16, 2025 for registration.
5. In the case of joint Shareholders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
6. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.
7. A Shareholder or his/her proxy should produce proof of identity when attending the AGM.

8. Contact information of the meeting:

Contact person: Zhuo Chen
Telephone: +86-18084866369
Email: yfchengz@kelun.com
Address: No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park,
Wenjiang District, Chengdu, Sichuan Province, PRC

9. Further details of the resolutions are set out in the circular of the Company dated May 21, 2025. Unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the circular.

10. References to dates and time in this notice are to Hong Kong dates and time.

As at the date of this notice, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.